Study of Antimicrobial Effects of Clarithromycin Loaded PLGA Nanoparticles against Clinical Strains of Helicobacter pylori

Abstract

Clarithromycin (CLR) formulation was prepared as PLGA nanoparticles in order to enhance the therapeutic effects using the distinctive features of a nanoparticulate delivery system. CLR loaded PLGA nanoparticles were prepared by Quasi Emulsion Solvent Diffusion (QESD) method using Poly lactic-co-Glycolic Acid (PLGA) as a biodegradable polymer. Antibacterial activity of the prepared formulations was evaluated against clinical strains of Helicobacter pylori, isolated from gastric biopsies of patients with gastritis, duodenal ulcer, peptic ulcer, and gastroesophageal reflux disease undergoing endoscopy, by using agar dilution method.

Spherical nanoparticles with relatively narrow size distribution (between 200 and 800 nm) in the size range of 305±138, 344±148 and 362±110 nm were achieved for F22, F23 and F23 respectively. CLR encapsulation percentages were measured to be 57.4±4.3 to 80.2±4.0%. CLR loaded PLGA nanoparticles showed equal or enhanced eradication effect against H. pylori strains according to the declined MIC values in comparison with the untreated CLR.

In conclusion, the prepared CLR nanoformulation showed appropriate physicochemical properties and improved activity against H. pylori that could be a suitable candidate for oral preparations.

Key words

clarithromycin - nanoparticles - helicobacter pylori - minimum inhibitory concentration

• References

• 1 Fakheri H, Bari Z, Aarabi M et al. Helicobacter pylori eradication in west asia: A review. World journal of gastroenterology 2014; 20: 10355-10367
• 2 Rafeey M, Ghotaslou R, Milani M et al. Association between helicobacter pylori, caga, and vaca status and clinical presentation in iranian children. Iranian journal of pediatrics 2013; 23: 551-556
• 3 Ghotaslou R, Milani M, Akhi MT et al. Diversity of helicobacter pylori caga and vaca genes and its relationship with clinical outcomes in azerbaijan, iran. Advanced pharmaceutical bulletin 2013; 3: 57-62
• 4 Milani M, Ghotaslou R, Akhi MT et al. The status of antimicrobial resistance of helicobacter pylori in eastern azerbaijan, iran: Comparative study according to demographics. Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy 2012; 18: 848-852
• 5 Ramteke S, Jain NK. Clarithromycin- and omeprazole-containing gliadin nanoparticles for the treatment of helicobacter pylori. Journal of drug targeting 2008; 16: 65-72
• 6 Valizadeh H, Mohammadi G, Ehyaei R et al. Antibacterial activity of clarithromycin loaded plga nanoparticles. Die Pharmazie 2012; 67: 63-68
• 7 Lotfipour F, Valizadeh H, Hallaj-Nezhadi S et al. Comparison of microbiological and high-performance liquid chromatographic methods for determination of clarithromycin levels in plasma. Iranian journal of pharmaceutical research 2010; 9: 27-35
• 8 Mohammadi G, Nokhodchi A, Barzegar-Jalali M et al. Physicochemical and anti-bacterial performance characterization of clarithromycin nanoparticles as colloidal drug delivery system. Colloids and surfaces B, Biointerfaces 2011; 88: 39-44
• 9 Abeylath SC, Turos E. Drug delivery approaches to overcome bacterial resistance to β-lactam antibiotics. Expert Opinion in Drug Delivery 2008; 5: 931-949
• 10 Zhang L, Pornpattananangku D, Hu CM et al. Development of nanoparticles for antimicrobial drug delivery. Current medicinal chemistry 2010; 17: 585-594
• 11 Zakeri-Milani P, Islambulchilar Z, Majidpour F et al. A study on enhanced intestinal permeability of clarithromycin nanoparticles. Brazilian Journal of Pharmaceutical Sciences 2014; 50: 121-129
• 12 Erah PO, Goddard AF, Barrett DA et al. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of helicobacter pylori infection. The Journal of antimicrobial chemotherapy 1997; 39: 5-12
• 13 Zakeri-Milani P, Valizadeh H, Ghanbarzadeh S et al. Pharmacokinetics and comparative bioavailability study of two clarithromycin suspensions following administration of a single oral dose to healthy volunteers. Arzneimittel-Forschung 2009; 59: 429-432
• 14 McNulty C, Owen R, Tompkins D et al. Group PHW . Helicobacter pylori susceptibility testing by disc diffusion. The Journal of antimicrobial chemotherapy 2002; 49: 601-609
• 15 Wikler MA. Performance standards for antimicrobial susceptibility testing: Eighteenth informational supplement. Clinical and Laboratory Standards Institute (CLSI). 2008
• 16 Salem II, Duzgunes N. Efficacies of cyclodextrin-complexed and liposome-encapsulated clarithromycin against mycobacterium avium complex infection in human macrophages. International journal of pharmaceutics 2003; 250: 403-414
• 17 Corrigan OI, Li X. Quantifying drug release from plga nanoparticulates. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences 2009; 37: 477-485
• 18 Valizadeh H, Nokhodchi A, Qarakhani N et al. Physicochemical characterization of solid dispersions of indomethacin with peg 6000, myrj 52, lactose, sorbitol, dextrin, and eudragit e100. Drug development and industrial pharmacy 2004; 30: 303-317
• 19 Reis CP, Neufeld R, Ribeiro AJ et al. Design of insulin-loaded alginate nanoparticles: Influence of the calcium ion on polymer gel matrix properties. Chemical Industry and Chemical Engineering Quarterly 2006; 12: 47-52